The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Open accessAbstract
Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that includes cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as AEs leading to increased infection risk such as cytopenias and hypogammaglobulinemia, and infections themselves. As preliminary data with this class of agents shows an increased risk of infections as compared with conventional MM treatment regimens, such as immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies (mAbs), guidance on infection monitoring, prophylaxis and treatment is required. This review provides consensus recommendations from a panel of 13 global experts, following a meeting in August 2022. The meeting objective was to review existing literature and identify relevant information on infections with all BsAbs in patients with MM, as well as to discuss clinical experience of experts in managing these infections. The recommendations outlined here can be used to guide management of infection risk factors, such as hypogammaglobulinemia and neutropenia. In addition, they can be used to guide the monitoring, prophylaxis, and treatment of bacterial, viral and fungal infections, including emerging infections of interest, such as coronavirus 2019 (COVID-19), and the use of vaccinations prior to and during BsAb treatment. The recommendations have been graded by the panel based on level of data available. Key recommendations include universal herpes simplex and varicella zoster virus prophylaxis, screening for hepatitis B virus reactivation risk in all patients, monthly intravenous immunoglobulin treatment for immunoparesis and in the absence of life-threatening infectious manifestations, use of colony-stimulating factors in patients with Grade 3 neutropenia, universal pneumocystis jirovecii pneumonia prophylaxis and no routine anti-fungal prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M., Ljungman, P. T., Chemaly, R. F., Maertens, J. A., Dadwal, S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706640 · Cited by 1,275
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 12×
“1% patients) received treatment with G-CSF [24].”
BackgroundResultInfluentialSelf-citationTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C. H., Holmberg, E. C., Mellqvist, U., Landgren, O., Björkholm, M., Hultcrantz, M. L., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2014) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 533
Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Bhutani, M., Karlin, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01338-6 · Cited by 353
Self-citationAnti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Krönke, J., Facon, T., Salnikov, A. V., Lesley, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02657 · Cited by 304
Self-citationCAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 277
Research works printed but not linked: 3
- Pfizer. Pfizer’s elranatamab granted FDA breakthrough therapy designation for relapsed or refractory multiple myeloma. 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy.
- Pfizer. Pfizer’s elranatamab receives FDA and EMA filing acceptance. 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-receives-fda-and-ema-filing-acceptance.
- Sebag, M. MagnetisMM-1: a study of elranatamab, a B-cell maturation antigen (BCMA)-targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma. ASH, 2021. · DOI · Paper page
Cited by
Sorted by citations
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
Self-citationLinvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma, N., Richter, J. R., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01008 · Cited by 191
Dimopoulos, M., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hájek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 188
Self-citationRodríguez‐Otero, P., Usmani, S. Z., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X. P., Pérez‐Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M., Einsele, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00043-3 · Cited by 157
Self-citationTalquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Cohen, Y. C., Magen, H., Gatt, M. E., Sébag, M., Kım, K., Min, C., Ocio, E. M., Yoon, S.-S., Chu, M. P., Rodríguez‐Otero, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2406536 · Cited by 118
Self-citation
Metadata
- Authors
- Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., Patel, K., Ramasamy, K., & Mateos, M.-V.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Universitätsklinikum Würzburg (DE)
- OhioHealth (US)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- Wilhelminen Hospital (AT)
- Centre Hospitalier Universitaire de Nantes (FR)
- The University of Texas MD Anderson Cancer Center (US)
- University of Oxford (GB)
- Corresponding author
- Raje, Noopur
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2023-08-01
- Volume
- 13
- Issue
- 1
- Pages
- 116-116
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC10394080
- OpenAlex
- W4385456897
- Cited by
- 209
- References
- 72
- Citations by year
- 2026: 81 · 2025: 64 · 2024: 54 · 2023: 10
- FWCI
- 43.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, bispecific antibodies, infection risk, infection control, infection treatment, hypogammaglobulinemia, neutropenia, COVID-19 pandemic, HBV reactivation, intravenous immunoglobulin, colony-stimulating factors, Pneumocystis carinii pneumonia prophylaxis, antifungal prophylaxis, viral and bacterial infections
- MeSH terms
- COVID-19, Agammaglobulinemia, Humans, Multiple Myeloma, Neutropenia, Antibodies, Bispecific, Neurotoxicity Syndromes, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
